Origen de la red de primer grado Lars Olsson.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 18 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Lars Olsson a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Consultant / Advisor Founder Private Equity Investor Private Equity Analyst | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Investor Relations Contact Director/Board Member Chief Tech/Sci/R&D Officer | |
| SPRUCE BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Private Equity Investor Chief Investment Officer | |
| NUCANA PLC | Biotechnology | Chairman Director/Board Member | |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Pharmaceuticals: Major | Corporate Officer/Principal Compliance Officer | |
Glionova AB
 Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IMAGO BIOSCIENCES, INC. | Biotechnology | Founder Director/Board Member | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of Uppsala | College/University | Doctorate Degree Graduate Degree | |
HealthCap Advisor AB
 HealthCap Advisor AB Investment ManagersFinance HealthCap Advisor AB provides investment advice. The private company is based in Stockholm, Sweden. | Investment Managers | Director/Board Member Corporate Officer/Principal | |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Microbiotica Ltd.
 Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Founder | |
| The University of Edinburgh | College/University | Doctorate Degree | |
SmithKline Beecham Ltd.
 SmithKline Beecham Ltd. Pharmaceuticals: MajorHealth Technology Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ALDEYRA THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Pasteur Merieux MSD Ltd. | President | ||
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Biotechnology | Chief Executive Officer | |
TOLMAR Therapeutics, Inc.
 TOLMAR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TOLMAR Therapeutics, Inc. provides healthcare services. The company's products include Eligard, a prostate cancer treatment, Aczone, a dermatology product for the treatment of acne, and Atrigel, a drug delivery system. Its drug delivery systems deliver medicines such as proteins and antibiotics. The company also makes Orajel and Cepacol mouth sore medicines. It is headquartered in Fort Collins, CO. | Pharmaceuticals: Major | Chairman | |
| MERSANA THERAPEUTICS, INC. | Biotechnology | Chairman | |
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Biotechnology | Director/Board Member | |
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Pharmaceuticals: Major | Director/Board Member | |
FluGen, Inc.
 FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | Pharmaceuticals: Major | Director/Board Member | |
| ALLENA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| The Johns Hopkins University | College/University | Doctorate Degree | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chairman | |
| University of Stockholm | College/University | Undergraduate Degree | |
| Immedica Pharma Holding AB | Director/Board Member | ||
| TTM HoldCo AB | Chief Executive Officer | ||
| RAYSEARCH LABORATORIES AB | Packaged Software | Director of Finance/CFO |
Estadísticas
Internacional
| Estados Unidos | 22 |
| Suecia | 16 |
| Reino Unido | 8 |
| Suiza | 6 |
| Países Bajos | 2 |
Sectorial
| Health Technology | 34 |
| Consumer Services | 6 |
| Finance | 4 |
| Commercial Services | 4 |
| Technology Services | 3 |
Operativa
| Director/Board Member | 159 |
| Corporate Officer/Principal | 36 |
| Chairman | 30 |
| Independent Dir/Board Member | 28 |
| Chief Tech/Sci/R&D Officer | 20 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Björn Ingemar Odlander | 53 |
| Dina Chaya | 23 |
| Johannes G. C. P. Schikan | 22 |
| Hugh Young Rienhoff | 21 |
| Marten Steen | 21 |
| David J. Clark | 21 |
| Bali Muralidhar | 20 |
| Genghis Lloyd-Harris | 19 |
| Anders Martin-Löf | 16 |
| Peder Sven Walberg | 15 |
| Andrew Kay | 14 |
| Birgitte Volck | 13 |
| Jonas Karl Hansson | 13 |
| Susan M. Flint | 10 |
| Thomas Plitz | 7 |
- Bolsa de valores
- Insiders
- Lars Olsson
- Conexiones Empresas
